NO327453B1 - Anvendelse av et alfa-amionoamid for fremstilling av et medikament for bruk som et smertestillende middel - Google Patents
Anvendelse av et alfa-amionoamid for fremstilling av et medikament for bruk som et smertestillende middel Download PDFInfo
- Publication number
- NO327453B1 NO327453B1 NO20003399A NO20003399A NO327453B1 NO 327453 B1 NO327453 B1 NO 327453B1 NO 20003399 A NO20003399 A NO 20003399A NO 20003399 A NO20003399 A NO 20003399A NO 327453 B1 NO327453 B1 NO 327453B1
- Authority
- NO
- Norway
- Prior art keywords
- sub
- propanamide
- hydrogen
- alkyl
- benzylamino
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 229940124641 pain reliever Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 208000002193 Pain Diseases 0.000 claims abstract description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
- 239000001257 hydrogen Substances 0.000 claims abstract description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 8
- 208000004296 neuralgia Diseases 0.000 claims abstract description 8
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 7
- 230000000202 analgesic effect Effects 0.000 claims abstract description 6
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 208000021722 neuropathic pain Diseases 0.000 claims abstract description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- -1 2-[4-(4-fluorobenzyloxy)benzyloxy]propanamide Chemical compound 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052731 fluorine Chemical group 0.000 claims description 4
- 239000011737 fluorine Chemical group 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 3
- QWRXERHYJYREES-UHFFFAOYSA-N 2-[[4-[(2-chlorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC=C1Cl QWRXERHYJYREES-UHFFFAOYSA-N 0.000 claims description 2
- BHJIBOFHEFDSAU-UHFFFAOYSA-N 2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-UHFFFAOYSA-N 0.000 claims description 2
- JFADNUHMEURSIM-UHFFFAOYSA-N 2-[[4-[(3-chlorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC(Cl)=C1 JFADNUHMEURSIM-UHFFFAOYSA-N 0.000 claims description 2
- JEARPZLCKWXTFT-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-2-methylpropanamide Chemical compound C1=CC(CNC(C)(C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 JEARPZLCKWXTFT-UHFFFAOYSA-N 0.000 claims description 2
- RLHPBZNGBNCVBL-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]-n-methylpropanamide Chemical compound C1=CC(CNC(C)C(=O)NC)=CC=C1OCC1=CC=CC(F)=C1 RLHPBZNGBNCVBL-UHFFFAOYSA-N 0.000 claims description 2
- NEMGRZFTLSKBAP-UHFFFAOYSA-N 2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide Chemical compound C1=CC(CNC(C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-UHFFFAOYSA-N 0.000 claims description 2
- DABZEFFZGNRXOC-UHFFFAOYSA-N 2-[methyl-[(4-phenylmethoxyphenyl)methyl]amino]propanamide Chemical compound C1=CC(CN(C)C(C)C(N)=O)=CC=C1OCC1=CC=CC=C1 DABZEFFZGNRXOC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- HXJYSYZXIYIPLJ-UHFFFAOYSA-N n,3-dimethyl-2-[(4-phenylmethoxyphenyl)methylamino]butanamide Chemical compound C1=CC(CNC(C(=O)NC)C(C)C)=CC=C1OCC1=CC=CC=C1 HXJYSYZXIYIPLJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000036407 pain Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000006742 locomotor activity Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- YKOCHIUQOBQIAC-YDALLXLXSA-N (2s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 YKOCHIUQOBQIAC-YDALLXLXSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000002485 Adiposis dolorosa Diseases 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000542 thalamic effect Effects 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- QNGQPQCXSOZZQG-SFHVURJKSA-N (2s)-2-[[4-[(3-cyanophenyl)methoxy]phenyl]methylamino]-3-hydroxy-n-methylpropanamide Chemical compound C1=CC(CN[C@@H](CO)C(=O)NC)=CC=C1OCC1=CC=CC(C#N)=C1 QNGQPQCXSOZZQG-SFHVURJKSA-N 0.000 description 1
- XINMWXLNOACQFQ-DFWYDOINSA-N (2s)-2-amino-3-hydroxy-n-methylpropanamide;hydrochloride Chemical compound Cl.CNC(=O)[C@@H](N)CO XINMWXLNOACQFQ-DFWYDOINSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- YAIQLSGJDFUANQ-UHFFFAOYSA-N 2-(benzylamino)propanamide Chemical class NC(=O)C(C)NCC1=CC=CC=C1 YAIQLSGJDFUANQ-UHFFFAOYSA-N 0.000 description 1
- IXIGOQRTYPMSPJ-UHFFFAOYSA-N 3-[(4-formylphenoxy)methyl]benzonitrile Chemical compound C1=CC(C=O)=CC=C1OCC1=CC=CC(C#N)=C1 IXIGOQRTYPMSPJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Foreliggende oppfinnelse vedrører anvendelse av et alfa-aminoamid for fremstilling av et medikament for bruk som et smertestillende middel, spesielt for lindring av kronisk eller neuropatisk smerte.
Kronisk og neuropatisk smerte er forbundet med forlenget vevs ødeleggelse eller skader i det perifere eller sentrale nervesystemet og forårsakes av et antall av komplekse forandringer i nociseptive baner.
Kliniske utslag av kronisk smerte inkluderer en følelse av forbrenning eller elektrisk sjokk, følelser av kroppslig distorsjon, allodynia og hyperpatia.
Til tross for det store antall av tilgjengelige smertestillende midler, er deres bruk begrenset av alvorlige bieffekter og beskjeden aktivitet ved noen smerte tilstander. Derfor er det fremdeles et klart behov for å utvikle nye forbindelser.
Internationale søknader WO 90/14334, WO 94/22808, WO 97/05102 og WO 97/05111 beskriver substituerte benzylaminopropionamid forbindelser som er aktive på sentralnervesystemet og nyttige som anti-epileptiske, anti-Parkinson, neuroprotektive, antidepressive, antispastiske og hypnotiske midler.
Foreliggende oppfinnelse vedrører anvendelse ved fremstilling av et medikament til bruk som et smertestillende middel, spesielt for lindring av kronisk eller neuropatisk smerte, av en forbindelse som er et alfa-aminoamid med formel (I)
der:
A er en -(CH2)v-0- gruppe der v er 1;
s er 1;
R er en fenylring eventuelt substituert med et halogenatom; Ri er hydrogen eller C i -C4 alkyl;
en av R2 og R3 er hydrogen og den andre er C1-C4 alkyl eller R2 og R3 er begge metyl; og
R4 er hydrogen eller C1-C4 alkyl;
enten som en enkel isomer eller en blanding derav, eller et farmasøytisk akseptabelt salt derav.
Alkyl eller alkoksy grupper kan være forgrenede eller rette grupper. Representative eksempler på C1-C4 alkyl grupper inkluderer metyl, etyl, n- og iso-propyl, n-, iso-, sec-og tert-butyl. <
Representative eksempler på C1-C4 alkoksy grupper inkluderer metoksy og etoksy.
Et halogen atom er fluor, brom, klor eller jod, spesielt klor eller fluor.
Farmasøytisk akseptable salter av forbindelsene i følge oppfinnelsen inkluderer syre addisjons salter med uorganiske, for eksempel salpeter syre, salt syre, hydrobrom syre, svovel syre, perklor syre og fosfor syre eller organiske, for eksempel eddik syre, trifluoreddik syre, propion syre, glykol syre, melke syre, oksal syre, malon syre, eple syre, malein syre, vin syre, sitron syre, benzo syre, kanel syre, mandel syre og salicyl syre.
Forbindelsene med formel (I) har asymmetriske karbon atomer og derfor kan de finnes enten som rasemiske blandinger eller som individuelle optiske isomere (enantiomere).
Følgelig inkluderer også foreliggende oppfinnelse innenfor dens omfang alle mulige isomerer og deres blandinger.
Foretrukne forbindelser med formel (I) er de der
A er en gruppe -(CH2)v-0- der v er 1;
s er 1;
R er en fenyl ring eventuelt substituert med klor eller fluor;
R1 er hydrogen eller C1-C4 alkyl;
en av R2 og R3 er hydrogen og den andre er d-C4 alkyl eller R2 og R3 er begge metyl; og
R4 er hydrogen eller metyl,
enten som en enkel isomer eller en blanding derav,
eller et farmasøytisk akseptabelt salt derav.
Eksempler på spesifikke forbindelser med formel (I) er: 2-[4-(3-fluorbenzyloksy)benzylamino]-2-metyl-propanamid;
2-[4-(3-fluorbenzyloksy)benzylamino]propanamid;
2-([4-benzyloksybenzylamino)propanamid;
2-[4-(2-fluorbenzyloksy)benzylamino]propanamid;
2-[4-(4-fluorbenzyloksy)benzyloksy]propanamid;
2-[4-(2-klorbenzyloksy)benzylamino]propanamid;
2-[4-(3-klorbenzyloksy)benzylamino]propanamid;
2- [4-(3 -fluorbenzyloksy) benzylamino] -N-metylpropanamid;
2-[N-(4-benzyloksybenzyl)-N-metyl-amino]propanamid;
2-(4-benzyloksybenzylamino)-3-metyl-N-metylbutanamid,
enten på form som en enkel isomer eller som en blanding derav, og de farmasøytisk akseptable saltene derav.
Neuropatiske og kroniske smerte tilstander hos et pattedyr kan således lindres og behandles. Eksempler på smerte tilstander som kan behandles ved en forbindelse med formel (I) inkluderer: - perifere neuropatier, slik som trigeminal neuralgi, postterapeutisk neuralgi, diabetisk neuropati, glossoparyngeal neuralgi, radikulopati, og neuropati som er sekundær i
forhold til metastatisk infiltrasjon, adiposis dolorosa og forbrennings smerte; og
- sentral smerte tilstander etterfulgt av slag, talamiske skader og multippel sklerose. "Behandling" slik det her brukes dekker enhver behandling av en tilstand hos et pattedyr, spesielt et menneske, og inkluderer: (i) å forebygge sykdommen fra å oppstå i en pasient som kan være pre disponert for sykdommen, men som ikke ennå har blitt diagnostisert til å ha den;
(ii) å hemme tilstanden, det vil si å stanse dens utvikling; eller
(iii) å lindre tilstanden, det vil si å forårsake tilbakegang av sykdommen.
Forbindelsene med formel (I) og de farmasøytiske akseptable saltene derav kan oppnås ved velkjente fremgangsmåter som beskrevet i de ovenfor anførte internasjonale søknadene.
Forbindelsene med formel (I) og de farmasøytisk akseptable saltene derav er heretter definert som "forbindelsene i følge oppfinnelsen" eller "de aktive midlene i følge oppfinnelsen".
Farmakologi
Som angitt over, er forbindelsene i følge oppfinnelsen aktive som smertestillende midler, som vist for eksempel ved at de har blitt funnet å være aktive i formalin testen.
Formalin test er et nyttig verktøy for å oppnå neurogenetisk inflammasjon og kontinuerlig smerte (Shibata et al, Pain, 38: 347-352,1989).
Formalin produserer en distinkt tofase respons. Den tidlige fasen synes å være forårsaket hovedsakelig av C-fiber aktivering på grunn av perifer stimulus, mens den sene fasen viser seg å være avhengig av kombinasjonen av en inflammatorisk reaksjon i det perifere vevet og funksjonelle endringer i det bakre "hornet" av ryggmargen. Disse funksjonelle endringene synes å være initiert ved C-fiber sperringen i løpet av den tidlige fasen (Tjolsen et al. Pain 51, 5-17,1992). Substans P og bradykinin tar del i den tidlige fasen, mens histamin, serotonin, prostaglandiner og bradykinin er involvert i den sene fasen.
Formalin test
NMPJ hannmus (22-25 g) fikk en injeksjon med 20 ml 2.7 % løsning av formalin inn i høyre bakpote og umiddelbart plassert inn i et observasjons kammer. Den kumulative bindings tiden av den injiserte poten ble registrert i den akutte fasen (0-5 min) og i den kroniske fasen (30-40 min) av den nekiseptive responsen av formalin.
De to representative forbindelsene (S)-2-[4-(3-fluorbenzyloksy)benzylamino]-propanamid, metansulfonat (intern kode PNU 151774E) og (S)-[2-[4-(3-fluorbenzyloksy)benzylamino]-2-metyl-propanamid (intern kode PNU 156654E) ble administrert 60 min før formalin injeksjon ved dosene på 7.5,15.0, 30.0 og 60.0 mg/kg; po. Morfin (5 mg/kg; sc) ble benyttet som en positiv standard. Aktivitets dataene ble analysert ved Dunnetfs t-test.
Lokomotorisk aktivitet og roterende stang ( rotarod)
Effektene av disse forbindelsene på lokomotorisk aktivitet og roterende stang (rotarod)
(en test for å evaluere bevegelses koordinasjon) ble studert for å ekskludere forandringer i disse parametrene som sammenblandende faktorer ved evalueringen av formalin
responsen. Den lokomotoriske aktivitets testen varte i 15 min. 5 min etter testingen av lokomotorisk aktivitet, ble musene satt på den roterende stangen (rotarod) i 2 min og antallet av mus som falt i løpet av denne tiden ble talt.
Forbindelser PNU 151774E og PNU 156654E ble testet ved dosene på 7.5,15.0, 30.0 og 60.0 mg/kg; po. Forbindelsene ble administrert 60 minutter før den lokomotoriske aktivitets testen.
Resultater
Forbindelser PNU 151774E og PNU 156654E reduserte dose avhengig den kumulative bindings tiden i begge fasene av formalin testen (tabell 1) hvilken demonstrerer smertestillende aktivitet uten noen effekt på lokomotorisk eller "rotarod" aktivitet (tabell 2).
I lys av deres biologiske aktivitet, er forbindelsene i følge oppfinnelsen nyttige for pattedyr, inkludert mennesker, som smertestillende midler. Spesielt er de nyttige i behandlingen av smerter forbundet med skade eller permanent endring av det perifere eller sentrale nervesystemet, for eksempel perifere neuropatier, slik som trigeminal neuralgi, postterapeutisk neuralgi, diabetisk neuropati, ratikullopati, glossofaryngeal neuralgi, og neuropati sekundær til metastatisk infiltrasjon, adiposis dolorosa, og forbrennings smerter; og sentralsmerte tilstander etterfulgt av slag, talamiske skader og multippel sklerose.
Tilstandene hos en pasient som har behov for et smertestillende middel kan således forbedres.
Forbindelsene i følge oppfinnelsen kan administreres ved et mangfold av doseformer, for eksempel oralt, på formen av tabletter, kapsler, sukker eller filmbelagte tabletter, væskeløsninger eller suspensjoner; rektalt på formen av stikkpillere; parenteralt, for eksempel intramuskulært, eller ved intravenøs injeksjon eller infusjon.
Dosen avhenger av alderen, vekten, tilstander hos pasienten og åv administrasjonsruten; for eksempel kan dosen som velges for oral administrasjon til voksne mennesker for eksempel for de representative forbindelsene
(S)-2-[4-(3-fluorbenzyloksy)benzylamino]-propanamid, metansulfonat, (S)-[2-[4-(3-fluorbenzyloksy)benzylamino]-2-metyl-propanamid, og (S)-[2-[4-(3-cyanobenzyloksy)benzylamino]-3-hydroksy-N-metylpropanamid strekke seg fra omtrent 1 til omtrent 500 mg pr dose, fra 1 til 5 ganger daglig.
For eksempel kan de faste orale formene inneholde, sammen med den aktive forbindelsen, fortynningsmidler, for eksempel laktose, dekstrose, sakarose, cellulose, maisstivelse eller potetstivelse; smøremidler, for eksempel silika, talkum, stearin syre, magnesium eller kalsium stearat, og/eller polyetylen glykoler; bindemidler, for eksempel stivelser, arabisk gummi, gelatin, metylcellulose, karboksymetylcellulose eller polyvinyl pyrrolidon; foreningsmidler, for eksempel en stivelse, algin syre, alginater eller natrium stivelse glykolat; skummende blandinger; fargestoffer; søtningsstoffer; fuktemidler slik som lecitin, polysorbater, laurylsulfater; og generelt ikke toksiske og farmakologisk uvirksomme substanser benyttet i farmasøytiske formuleringer. Nevnte farmasøytiske preparater kan fremstilles på kjent måte, for eksempel, ved hjelp av blanding, granulering, tablettering, sukkerbelegging, eller film beleggings fremgangsmåter.
Væske dispersjonen for oral administrasjon kan for eksempel være siruper, emulsjoner og suspensjoner.
Sirupene kan inneholde en bærer, for eksempel sakkarose eller sakkarose med glyserin og/eller mannitol og/eller sorbitol.
Suspensjonen og emulsjonen kan inneholde som bærer, for eksempel en naturlig gummi, agar, natrium alginat, pektin, metylcellulose, karboksymetylcellulose, eller polyvinyl alkohol.
Suspensjonen eller løsningene for intramuskulær injeksjoner kan inneholde, sammen med den aktive forbindelsen, en farmasøytisk akseptabel bærer, for eksempel sterilt vann, olivenolje, etyl oleat, glykoler, for eksempel propylen glykol, og, om ønskelig, en egnet mengde av lidokain hydroklorid. Løsningene for intravenøse injeksjoner eller infusjoner kan inneholde som bærer, for eksempel, sterilt vann eller foretrukket kan de være på formen av sterile, vandige, isotoniske saltløsninger.
Stikkpillene kan inneholde sammen med den aktive forbindelsen, en farmasøytisk akseptabel bærer, for eksempel kakao smør, polyetylen glykol, et polyoksyetylen sorbitan fett syre ester overflate aktivt middel eller lecitin.
Referanse eksempel 1
(S)-2-[4-(3-cyanobenzyloksy)benzylamino]-3-hydroksy-N-metyl-propanamid Til en løsning av N-metylserinamid hydroklorid (2 g; 0.0129 mol), i metanol tilsettes (40 ml), 2 g pulverisert 3 A molekyl sil; etter røring i 15 min ved romtemperatur, tilsettes 0.65 g (0.0102 mol) natrium cyanoborhydrid i en enkelt porsjon etterfulgt av 2.85 g (0.012 mol) 4-(3-cyanobenzyloksy)benzaldehyd. Blandingen røres i 2 timer ved romtemperatur, filtreres deretter og resten etter fordampning separeres ved flash kromatografi på silikagel (eluent: kloroform 98: metanol 2: 30 % NH40H 0.2). 2.6 g (63 %) av ren tittel forbindelse (smp. 130-134 °C).
[a]D:+12.8 (c = 1.25 AcOH)
Referanse eksempel 2
(S)-[2-[4-(3-cyanobenzyloksy)benzyl]-2-metyl-amino]-3-hydroksy-N-metylpropanamid
(2 g; 0.0059 mol) oppløses i metanol (30 ml) og 1.8 g (0.013 mol) av vannfritt kalium karbonat tilsettes til løsningen. Metyl jodid (1.5 ml; 0.025 mol) dryppes til blandingen som røres i 2 timer ved romtemperatur og deretter fordampes til tørrhet. Rå resten kromatograferes på silikagel (eluent: kloroform/metanol; 95/5). 1.88 g (90 %) (S)-[2-[4-(3-cyanobenzyloksy)benzyl]-2-metyl-amino]-3-hydroksy-N-metyl-propanamid oppnås. Element analyse:
Referanse eksempel 3
Med de vanlige fremgangsmåtene av farmasøytiske teknikker, kan fremstillingen av kapsler med den følgende sammensetningen foretas:
Claims (7)
1.
Anvendelse ved fremstilling av et medikament til bruk som et smertestillende middel, av en forbindelse som er et alfa-aminoamid med formel (I)
der: A er en -{CH2)v-0- gruppe der v er 1; s er 1; R er en fenylring eventuelt substituert med et halogenatom; Ri er hydrogen eller C1-C4 alkyl; en av R2 og R3 er hydrogen og den andre er C1-C4 alkyl eller R2 og R3 er begge metyl; og R4 er hydrogen eller C1-C4 alkyl; enten som en enkel isomer eller en blanding derav, eller et farmasøytisk akseptabelt salt derav.
2.
Anvendelse ifølge krav 1, der medikamentet er til behandlingen eller lindringen av kronisk eller neuropatisk smerte.
3.
Anvendelse ifølge krav 1, der i formel (I)
A er en gruppe -( CHih- O- der v er 1;
s er 1;
R er en fenyl ring eventuelt substituert med klor eller fluor;
Ri er hydrogen eller C1-C4 alkyl;
en av R2 og R3 er hydrogen og den andre er C1-C4 alkyl eller R2 og R3 er begge metyl; og
R4 er hydrogen eller metyl,
enten som en enkel isomer eller en blanding derav,
eller et farmasøytisk akseptabelt salt derav.
4.
Anvendelse i følge krav 1, der forbindelsen er valgt fra:
2- [4-(3 -fluorbenzyloksy)benzylamino] -2-metyl-propanamid; 2-[4-(3-fluorbenzyloksy)benzylamino]propanamid; 2-([4-benzyloksybenzylamino)propanamid; 2-[4-(2-fluorbenzyloksy)benzylamino]propanamid; 2-[4-(4-fluorbenzyloksy)benzyloksy]propanamid; 2-[4-(2-klorbenzyloksy)benzylamino]propanamid; 2-[4-(3-klorbenzyloksy)benzylamino]propanamid; 2-[4-(3-fluorbenzyloksy) benzylamino]-N-metylpropanamid; 2-[N-(4-benzyloksybenzyl)-N-metyl-amino]propanamid; 2-(4-benzyloksybenzylamino)-3-metyl-N-metylbutanamid,
på formen enten som en enkel isomer eller som en blanding derav, eller et farmasøytisk akseptabelt salt derav.
5.
Anvendelse ifølge krav 4, der forbindelsen er (S)-2-[4-(3-fluorenzyloksy)benzylamino)propanamid eller et farmasøytisk akseptabelt salt derav.
6.
Anvendelse ifølge krav 5, der det farmasøytisk akseptable saltet er et salt med metansulfonsyre.
7.
Anvendelse ifølge krav 4, der forbindelsen er (S)-2-[4-(2-fluorbenzyloksy)benzylamino]propanamid eller et farmasøytisk akseptabelt salt derav.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9727523.4A GB9727523D0 (en) | 1997-12-31 | 1997-12-31 | Alpha-aminoamide derivatives useful as analgesic agents |
PCT/EP1998/008157 WO1999035125A1 (en) | 1997-12-31 | 1998-12-12 | Alpha-aminoamide derivatives useful as analgesic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20003399D0 NO20003399D0 (no) | 2000-06-29 |
NO20003399L NO20003399L (no) | 2000-08-02 |
NO327453B1 true NO327453B1 (no) | 2009-07-06 |
Family
ID=10824342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20003399A NO327453B1 (no) | 1997-12-31 | 2000-06-29 | Anvendelse av et alfa-amionoamid for fremstilling av et medikament for bruk som et smertestillende middel |
Country Status (19)
Country | Link |
---|---|
US (2) | USRE40259E1 (no) |
EP (1) | EP1045830B1 (no) |
JP (1) | JP4410930B2 (no) |
KR (1) | KR100525587B1 (no) |
AT (1) | ATE238273T1 (no) |
BR (1) | BR9814548A (no) |
CA (1) | CA2316902C (no) |
DE (1) | DE69813896T2 (no) |
DK (1) | DK1045830T3 (no) |
EA (1) | EA002763B1 (no) |
ES (1) | ES2194392T3 (no) |
GB (1) | GB9727523D0 (no) |
HK (1) | HK1028020A1 (no) |
HU (1) | HU228995B1 (no) |
IL (2) | IL136734A0 (no) |
NO (1) | NO327453B1 (no) |
NZ (1) | NZ505440A (no) |
PT (1) | PT1045830E (no) |
WO (1) | WO1999035125A1 (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479484B1 (en) * | 1997-11-21 | 2002-11-12 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
US20040019046A1 (en) * | 2000-11-27 | 2004-01-29 | Paolo Pevarello | Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
US6476068B1 (en) | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
EP1438956A1 (en) * | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
WO2004087125A1 (en) * | 2003-04-02 | 2004-10-14 | Ionix Pharmaceuticals Limited | Amino acid derivatives as inhibitors of mammalian sodium channels |
AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
WO2005000309A2 (en) * | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
PL1658062T3 (pl) * | 2003-08-25 | 2010-07-30 | Newron Pharm Spa | Pochodne alfa-aminoamidu jako środki przeciwzapalne |
EP1524267A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Substituted benzylaminoalkylene heterocycles |
EP1533302A1 (en) * | 2003-11-21 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | Histidine derivatives |
EP1533298A1 (en) * | 2003-11-21 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | 3-aminopyrrolidone derivatives |
EP1535908A1 (en) | 2003-11-24 | 2005-06-01 | Newron Pharmaceuticals S.p.A. | N-acyl-N'-benzyl-alkylendiamino drivatives |
EP1533295A1 (en) | 2003-11-24 | 2005-05-25 | Newron Pharmaceuticals S.p.A. | Cyclopentyl Derivatives |
EP1557166A1 (en) * | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
CN101018546B (zh) * | 2004-09-10 | 2013-06-12 | 纽朗制药有限公司 | 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类 |
TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
JP5139307B2 (ja) * | 2005-10-10 | 2013-02-06 | グラクソ グループ リミテッド | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 |
TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
NZ567540A (en) | 2005-12-22 | 2010-07-30 | Newron Pharm Spa | 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators |
EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
CA2653012C (en) | 2006-06-19 | 2014-08-05 | Newron Pharmaceuticals S.P.A. | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino) propan amides |
PT2155663T (pt) | 2007-06-15 | 2018-01-16 | Newron Pharm Spa | Derivados de 2-[2-(fenil)etilamino]alcanamida substituídos e sua utilização como moduladores dos canais de sódio e/ou de cálcio |
CN101896456B (zh) | 2007-12-11 | 2014-10-22 | 纽朗制药有限公司 | 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法 |
EP2314569A1 (en) | 2009-10-22 | 2011-04-27 | Merck Patent GmbH | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof |
HUE030504T2 (en) | 2010-04-27 | 2017-05-29 | Newron Pharm Spa | Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers |
SG11201500377UA (en) | 2012-09-10 | 2015-02-27 | Hoffmann La Roche | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
WO2015102390A1 (ko) * | 2013-12-30 | 2015-07-09 | 이화여자대학교 산학협력단 | 신규한 아미드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 통증의 예방 또는 치료용 약학적 조성물 |
US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
CN107522654B (zh) * | 2016-06-21 | 2020-09-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 新的α-氨基酰胺衍生物及其医药用途 |
WO2019071162A2 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1140748A (en) | 1966-06-23 | 1969-01-22 | Ici Ltd | New carboxylic acid derivatives |
US3658967A (en) | 1966-06-23 | 1972-04-25 | Ici Ltd | Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood |
CH480308A (de) | 1966-08-11 | 1969-10-31 | Ciba Geigy | Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen |
US4049663A (en) * | 1972-06-06 | 1977-09-20 | Allen & Hanburys Limited | Ethylene diamine derivatives |
US4311853A (en) | 1979-02-06 | 1982-01-19 | The Radiochemical Centre Limited | Selenium derivatives of thyroxine and tri-iodothyronine |
DE3010599A1 (de) | 1979-03-22 | 1980-10-09 | Continental Pharma | Derivate von glycinamid, deren herstellung und verwendung |
US4267354A (en) | 1979-04-25 | 1981-05-12 | E. R. Squibb & Sons, Inc. | Substituted amides having antiinflammatory activity and intermediates |
ZA805476B (en) | 1979-09-26 | 1981-11-25 | Robins Co Inc A H | 2-amino-3-benzoyl-phenylacetamides and cyclic homologues |
FR2480747A1 (fr) | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
EP0144853B1 (en) | 1983-11-21 | 1990-09-26 | Fujisawa Pharmaceutical Co., Ltd. | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
US4631287A (en) | 1985-04-16 | 1986-12-23 | Usv Pharmaceutical Corp. | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
US4725619A (en) | 1985-04-16 | 1988-02-16 | Usv Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
US4839369A (en) | 1985-04-16 | 1989-06-13 | Rorer Pharmaceutical Corporation | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments |
GB8714901D0 (en) | 1986-07-23 | 1987-07-29 | Ici Plc | Amide derivatives |
GB2216515A (en) | 1988-03-04 | 1989-10-11 | Nippon Shinyaku Co Ltd | Acylphenol derivatives |
IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
US5153226A (en) | 1989-08-31 | 1992-10-06 | Warner-Lambert Company | Acat inhibitors for treating hypocholesterolemia |
EP0525360B1 (en) | 1991-07-30 | 1998-03-25 | Korea Research Institute Of Chemical Technology | Novel phenylacetamide derivatives and processes for the preparation thereof |
US5498610A (en) | 1992-11-06 | 1996-03-12 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
GB9306886D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation |
GB9306899D0 (en) | 1993-04-01 | 1993-05-26 | Erba Carlo Spa | Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation |
US5475007A (en) | 1993-05-28 | 1995-12-12 | The Regents Of The University Of California | 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof |
US5482964A (en) | 1994-10-11 | 1996-01-09 | Warner-Lambert Company | Substituted phenoxyhydroxypropyl amines as central nervous system agents |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
KR0147963B1 (ko) | 1995-01-10 | 1998-08-17 | 강박광 | 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법 |
US5849737A (en) | 1995-04-14 | 1998-12-15 | The Regents Of The University Of California | Compositions and methods for treating pain |
US5741818A (en) | 1995-06-07 | 1998-04-21 | University Of Saskatchewan | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
GB9515411D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | N-(4-substituted-benzyl)-2-aminolactam derivatives |
GB9515412D0 (en) * | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
US5688830A (en) | 1996-01-25 | 1997-11-18 | Syntex (U.S.A.) Inc. | Treatment of neuropathic pain |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
GB9706730D0 (en) | 1997-04-03 | 1997-05-21 | Pharmacia & Upjohn Spa | 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives |
AU738197C (en) | 1997-04-22 | 2002-05-16 | Cocensys, Inc. | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof |
US6479484B1 (en) | 1997-11-21 | 2002-11-12 | Euro-Celtique S.A. | Substituted 2-aminoacetamides and the use thereof |
GB9727521D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Substituted 2-benzylamino-2-phenyl-acetamide compounds |
IL137671A0 (en) | 1998-02-04 | 2001-10-31 | Euro Celtique Sa | Semicarbazide derivatives and pharmaceutical compositions containing the same |
US6281211B1 (en) | 1999-02-04 | 2001-08-28 | Euro-Celtique S.A. | Substituted semicarbazides and the use thereof |
ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
EP1438956A1 (en) | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
AR044007A1 (es) | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
-
1997
- 1997-12-31 GB GBGB9727523.4A patent/GB9727523D0/en not_active Ceased
-
1998
- 1998-12-12 HU HU0100870A patent/HU228995B1/hu unknown
- 1998-12-12 WO PCT/EP1998/008157 patent/WO1999035125A1/en active IP Right Grant
- 1998-12-12 IL IL13673498A patent/IL136734A0/xx active IP Right Grant
- 1998-12-12 CA CA002316902A patent/CA2316902C/en not_active Expired - Lifetime
- 1998-12-12 DE DE69813896T patent/DE69813896T2/de not_active Expired - Lifetime
- 1998-12-12 NZ NZ505440A patent/NZ505440A/en not_active IP Right Cessation
- 1998-12-12 JP JP2000527527A patent/JP4410930B2/ja not_active Expired - Lifetime
- 1998-12-12 PT PT98966617T patent/PT1045830E/pt unknown
- 1998-12-12 EA EA200000731A patent/EA002763B1/ru not_active IP Right Cessation
- 1998-12-12 ES ES98966617T patent/ES2194392T3/es not_active Expired - Lifetime
- 1998-12-12 EP EP98966617A patent/EP1045830B1/en not_active Expired - Lifetime
- 1998-12-12 US US11/359,982 patent/USRE40259E1/en not_active Expired - Lifetime
- 1998-12-12 AT AT98966617T patent/ATE238273T1/de active
- 1998-12-12 KR KR10-2000-7007229A patent/KR100525587B1/ko not_active IP Right Cessation
- 1998-12-12 BR BR9814548-7A patent/BR9814548A/pt not_active Application Discontinuation
- 1998-12-12 DK DK98966617T patent/DK1045830T3/da active
- 1998-12-12 US US09/582,198 patent/US6306903B1/en not_active Ceased
-
2000
- 2000-06-13 IL IL136734A patent/IL136734A/en not_active IP Right Cessation
- 2000-06-29 NO NO20003399A patent/NO327453B1/no not_active IP Right Cessation
- 2000-11-20 HK HK00107398A patent/HK1028020A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DK1045830T3 (da) | 2003-08-04 |
HU228995B1 (en) | 2013-07-29 |
ES2194392T3 (es) | 2003-11-16 |
EP1045830B1 (en) | 2003-04-23 |
NO20003399D0 (no) | 2000-06-29 |
CA2316902A1 (en) | 1999-07-15 |
PT1045830E (pt) | 2003-08-29 |
JP2002508302A (ja) | 2002-03-19 |
US6306903B1 (en) | 2001-10-23 |
KR20010033706A (ko) | 2001-04-25 |
HUP0100870A2 (hu) | 2001-07-30 |
IL136734A (en) | 2007-03-08 |
EA200000731A1 (ru) | 2001-02-26 |
JP4410930B2 (ja) | 2010-02-10 |
IL136734A0 (en) | 2001-06-14 |
KR100525587B1 (ko) | 2005-11-03 |
DE69813896D1 (de) | 2003-05-28 |
USRE40259E1 (en) | 2008-04-22 |
EP1045830A1 (en) | 2000-10-25 |
CA2316902C (en) | 2006-06-06 |
WO1999035125A1 (en) | 1999-07-15 |
EA002763B1 (ru) | 2002-08-29 |
GB9727523D0 (en) | 1998-02-25 |
BR9814548A (pt) | 2000-10-10 |
ATE238273T1 (de) | 2003-05-15 |
DE69813896T2 (de) | 2003-11-06 |
NO20003399L (no) | 2000-08-02 |
HK1028020A1 (en) | 2001-02-02 |
HUP0100870A3 (en) | 2002-11-28 |
NZ505440A (en) | 2002-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO327453B1 (no) | Anvendelse av et alfa-amionoamid for fremstilling av et medikament for bruk som et smertestillende middel | |
US7718815B2 (en) | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | |
US20030018061A1 (en) | Novel remedies with the use of beta 3 agonist | |
CA2316082C (en) | Substituted 2-benzylamino-2-phenyl-acetamide compounds | |
NZ262907A (en) | Phenylalkyloxybenzylaminoacetamide, derivatives thereof and medicaments | |
CA2536764A1 (en) | .alpha.-aminoamide derivatives useful as anti-inflammatory agents | |
MXPA00006352A (en) | Alpha-aminoamide derivatives useful as analgesic agents | |
WO2019099760A1 (en) | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | |
MXPA00006354A (en) | Substituted 2-benzylamino-2-phenyl-acetamide compounds | |
MXPA06008188A (en) | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |